MedTrace Logo

A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer

NCT02000947 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 459

Last updated 2019-10-31

No results posted yet for this study

Summary

The purpose of this study is to determine if MEDI4736 will be adequately tolerated in combination with tremelimumab in subjects with advanced non-small cell lung cancer (NSCLC).

Conditions

Interventions

DRUG

MEDI4736

MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb).

DRUG

Tremelimumab

Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).

DRUG

tremelimumab

Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Principal Investigators

  • MedImmune LLC · MedImmune LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
101 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-25
Primary Completion
2019-09-17
Completion
2019-09-17
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • France
  • Italy
  • South Korea
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02000947 on ClinicalTrials.gov